A Study in Patients With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)



Status:Recruiting
Healthy:No
Age Range:18 - Any
Updated:3/14/2019
Start Date:January 2015
End Date:November 2022
Contact:Patrick Yue, M.D.
Email:ClinicalTrials@portola.com
Phone:650.246.7000

Use our guide to learn which trials are right for you!

Prospective, Open-Label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor Who Have Acute Major Bleeding (ANNEXA-4)

The purpose of this study is to evaluate the hemostatic efficacy of andexanet alfa in
patients receiving a factor Xa inhibitor who are experiencing an acute major bleed. The
safety of andexanet will also be studied.


Inclusion:

1. Acute major bleeding episode requiring urgent reversal of anticoagulation; defined by
at least one of the following:

- Acute bleeding that is potentially life-threatening, OR

- Acute bleeding associated with a fall in hemoglobin level by ≥2 g/dL, OR

- Acute bleeding associated with a hemoglobin level of ≤8 g/dL if no baseline
hemoglobin is available, OR

- Acute bleeding in a critical area or organ such as intraspinal, pericardial, or
intracranial.

2. If bleeding is intracranial or intraspinal, the patient must have undergone a head CT
or MRI scan demonstrating the bleeding.

3. Patient received or is believed to have received one of the following within 18 hours
prior to andexanet administration: apixaban, rivaroxaban, edoxaban or enoxaparin.

4. For patients with intracranial bleeding, there must be a reasonable expectation that
andexanet treatment will commence within 2 hours of the baseline imaging evaluation.

Exclusion:

1. The patient is scheduled to undergo surgery in less than 12 hours, with the exception
of minimally invasive surgery/procedures.

2. A patient with an intracerebral hemorrhage has any of the following:

- Glasgow coma score < 7, OR

- Intracerebral hematoma > 60 cc as assessed by CT or MRI

3. Patients with visible, musculoskeletal or intra-articular bleeding as their qualifying
bleed.

4. Expected survival of less than 1 month

5. Recent history (within 2 weeks) of a diagnosed thrombotic event (TE) as follows:
venous thromboembolism, myocardial infarction, disseminated intravascular coagulation
(DIC), cerebral vascular accident, transient ischemic attack, unstable angina pectoris
hospitalization or severe peripheral vascular disease within 2 weeks prior to
screening.

6. Severe sepsis or septic shock at the time of Screening.

7. Pregnant or a lactating female.

8. Patient has received any of the following drugs or blood products within 7 days of
Screening:

- Vitamin K antagonist (VKA)

- Dabigatran

- Prothrombin Complex Concentrate products (PCC) or recombinant factor VIIa
(rfVIIa)

- Whole blood, plasma fractions

9. Treated with an investigational drug <30 days prior to Screening

10. Planned administration of PCC, fresh frozen plasma (FFP) or rfVIIa from Screening
until within 12 hours after the end of the andexanet infusion.
We found this trial at
24
sites
Asheville, North Carolina
Phone: 650-246-7000
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Annapolis, Maryland
Phone: 650-246-7000
?
mi
from
Annapolis, MD
Click here to add this to my saved trials
Austin, Texas
Phone: 650-246-7000
?
mi
from
Austin, TX
Click here to add this to my saved trials
Boston, Massachusetts
Phone: 650-246-7000
?
mi
from
Boston, MA
Click here to add this to my saved trials
Bruxelles,
Phone: 650-246-7000
?
mi
from
Bruxelles,
Click here to add this to my saved trials
Chapel Hill, North Carolina
Phone: 650-246-7000
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Cincinnati, Ohio
Phone: 650-246-7000
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cleveland, Ohio
Phone: 650-246-7000
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Detroit, Michigan
Phone: 650-246-7000
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Fort Lauderdale, Florida
Phone: 650-246-7000
?
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Fort Worth, Texas
Phone: 650-246-7000
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Huntington, West Virginia
Phone: 650-246-7000
?
mi
from
Huntington, WV
Click here to add this to my saved trials
Jacksonville, Florida
Phone: 650-246-7000
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Long Beach, California
Phone: 650-246-7000
?
mi
from
Long Beach, CA
Click here to add this to my saved trials
Los Angeles, California
Phone: 650-246-7000
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Orange, California
Phone: 650-246-7000
?
mi
from
Orange, CA
Click here to add this to my saved trials
Pittsburgh, Pennsylvania
Phone: 650-246-7000
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Raleigh, North Carolina
Phone: 650-246-7000
?
mi
from
Raleigh, NC
Click here to add this to my saved trials
Rochester, New York
Phone: 650-246-7000
?
mi
from
Rochester, NY
Click here to add this to my saved trials
Royal Oak, Michigan
Phone: 650-246-7000
?
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Phone: 650-246-7000
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Sarasota, Florida
Phone: 650-246-7000
?
mi
from
Sarasota, FL
Click here to add this to my saved trials
Tampa, Florida
Phone: 650-246-7000
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Troy, Michigan
Phone: 650-246-7000
?
mi
from
Troy, MI
Click here to add this to my saved trials